Download PDF
CC BY-NC-ND 4.0 · J Neurol Surg Rep 2023; 84(01): e1-e5
DOI: 10.1055/a-1996-1283
Case Report

SMARCB1(INI-1)-Deficient Sinonasal Carcinoma: An Evolving Entity

Sei Y. Chung 
1   Department of Otolaryngology-Head and Neck Surgery, The University of Texas Southwestern Medical Center Ringgold Standard Institution, Dallas, Texas, United States
,
Parker Kenee
1   Department of Otolaryngology-Head and Neck Surgery, The University of Texas Southwestern Medical Center Ringgold Standard Institution, Dallas, Texas, United States
,
Tanner Mitton
1   Department of Otolaryngology-Head and Neck Surgery, The University of Texas Southwestern Medical Center Ringgold Standard Institution, Dallas, Texas, United States
,
Ashleigh Halderman
1   Department of Otolaryngology-Head and Neck Surgery, The University of Texas Southwestern Medical Center Ringgold Standard Institution, Dallas, Texas, United States
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Abstract

SMARCB1(INI-1)-deficient sinonasal carcinoma is a rare, poorly differentiated neoplasm with a poor prognosis. Though historically most were identified as sinonasal undifferentiated carcinoma, we now understand it to be a distinct entity. There is currently a general consensus supporting multimodal therapy, though the optimal sequence of surgery, chemotherapy, and radiation has yet to be defined.

Keywords

sinonasal carcinoma - SMARCB1 - INI-1 - SMARCB1(INI-1)-deficient - sinonasal undifferentiated carcinoma - SNUC - SWItch/Sucrose non-fermentable - SWI/SNF - EZH2


Publication History

Received: 15 November 2022

Accepted: 23 November 2022

Accepted Manuscript online:
10 December 2022

Article published online:
16 January 2023

© 2023. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Agaimy A, Franchi A, Lund VJ. et al. Sinonasal undifferentiated carcinoma (SNUC): from an entity to morphologic pattern and back again-a historical perspective. Adv Anat Pathol 2020; 27 (02) 51-60
    CrossrefPubMedGoogle Scholar
  • 2 Agaimy A, Hartmann A, Antonescu CR. et al. SMARCB1 (INI-1)-deficient sinonasal carcinoma: a series of 39 cases expanding the morphologic and clinicopathologic spectrum of a recently described entity. Am J Surg Pathol 2017; 41 (04) 458-471
    CrossrefPubMedGoogle Scholar
  • 3 Bishop JA, Westra WH. NUT midline carcinomas of the sinonasal tract. Am J Surg Pathol 2012; 36 (08) 1216-1221
    CrossrefPubMedGoogle Scholar
  • 4 Bishop JA, Antonescu CR, Westra WH. SMARCB1 (INI-1)-deficient carcinomas of the sinonasal tract. Am J Surg Pathol 2014; 38 (09) 1282-1289
    CrossrefPubMedGoogle Scholar
  • 5 Bishop JA. Recently described neoplasms of the sinonasal tract. Semin Diagn Pathol 2016; 33 (02) 62-70
    CrossrefPubMedGoogle Scholar
  • 6 Roberts CW, Orkin SH. The SWI/SNF complex–chromatin and cancer. Nat Rev Cancer 2004; 4 (02) 133-142
    CrossrefPubMedGoogle Scholar
  • 7 Wilson BG, Roberts CW. SWI/SNF nucleosome remodellers and cancer. Nat Rev Cancer 2011; 11 (07) 481-492
    CrossrefPubMedGoogle Scholar
  • 8 Masliah-Planchon J, Bièche I, Guinebretière JM, Bourdeaut F, Delattre O. SWI/SNF chromatin remodeling and human malignancies. Annu Rev Pathol 2015; 10: 145-171
    CrossrefPubMedGoogle Scholar
  • 9 Pasini D, Di Croce L. Emerging roles for Polycomb proteins in cancer. Curr Opin Genet Dev 2016; 36: 50-58
    CrossrefPubMedGoogle Scholar
  • 10 Yamaguchi H, Hung MC. Regulation and role of EZH2 in cancer. Cancer Res Treat 2014; 46 (03) 209-222
    CrossrefPubMedGoogle Scholar
  • 11 Lee VH, Tsang RK. Lo AWI, et al. SMARCB1 (INI-1)-deficient sinonasal carcinoma: a systematic review and pooled analysis of treatment outcomes. Cancers (Basel) 2022; 14 (13) 3285
    CrossrefPubMedGoogle Scholar
  • 12 Parsel SM, Jawad BA, McCoul ED. SMARCB1-deficient sinonasal carcinoma: systematic review and case report. World Neurosurg 2020; 136: 305-310
    CrossrefPubMedGoogle Scholar
  • 13 Chitguppi C, Rabinowitz MR, Johnson J. et al. Loss of SMARCB1 expression confers poor prognosis to sinonasal undifferentiated carcinoma. J Neurol Surg B Skull Base 2020; 81 (06) 610-619
    Article in Thieme ConnectPubMedGoogle Scholar
  • 14 Institute NC. Nivolumab and Ipilimumab in Treating Patients with Rare Tumors. Available at: https://www.clinicaltrials.gov/ct2/show/NCT02834013?recrs=abc&lupd_s=08%2F01%2F2021
    PubMedGoogle Scholar
  • 15 Institute NC. Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial). Available at: https://clinicaltrials.gov/ct2/show/NCT03213665
    PubMed